Scientist-led leadership in PPI oncology discovery

PPI Pharmaceuticals is led by Campbell McInnes, Ph.D., President and Chief Scientific Officer, with advisory support from academic collaborators in cancer pharmacology and cell biology.

President and Chief Scientific Officer

Education

Ph.D. in Organic Chemistry, University of Edinburgh, Scotland, UK (1991)
Postdoctoral training in protein structural biology, University of Alberta, Canada

President and Chief Scientific Officer

Campbell McInnes, Ph.D.

Professor in Medicinal Chemistry, University of South Carolina

Experience

Campbell McInnes, Ph.D., has 30 years of research experience, including 22 years in cancer drug discovery. He trained in organic chemistry and protein structural biology, then led structure-based design at Cyclacel Inc in the United Kingdom, a company started by Prof. Sir David Lane, co-discoverer of the p53 protein, before joining the University of South Carolina in 2006.

Head of the Structure Based Design Group, Cyclacel Inc, Dundee, UK
Joined the University of South Carolina in 2006

Recent publications on PubMed

Advisors and collaborators

Consultant and Advisory Board Member

Michael Wyatt, Ph.D.

Professor of Biomedicinal Chemistry, University of South Carolina

Advisor supporting cancer pharmacology strategy and translational evaluation of PPI Pharmaceuticals’ inhibitor programs.

30 years of research experience in cancer pharmacology
Ph.D. in Molecular Pharmacology, University College London (1996)
Postdoctoral training in Genetic Toxicology, Harvard School of Public Health
Joined USC in 1999

Research Collaborator

Danda Chapagai, Ph.D.

Graduate research in Dr. Wyatt’s laboratory, University of South Carolina

Collaborator contributing cancer cell culture studies that inform the biological evaluation of REPLACE-derived compounds.

Graduate student in Dr. Wyatt’s laboratory
Cancer cell culture supporting phenotypic characterization of candidate inhibitors